Two-year outcomes in patients with mild refractory angina treated with enhanced external counterpulsation

Clinical Cardiology
William E LawsonInternational Enhanced External Counterpulsation Patient Registry Investigators

Abstract

In the International Enhanced External Counterpulsation Patient Registry (IEPR), approximately 85% of the patients treated are in Canadian Cardiovascular Society (CCS) class III-IV with no option for further invasive coronary revascularization procedures. This study sought to determine whether it is clinically important to establish whether the observed durable reduction in disabling severe angina with enhanced external counterpulsation (EECP) treatment can be extended to those with less severe CCS class II angina, who also have no option for further revascularization. This study evaluated the immediate response, durability and clinical events over a 2-year period after EECP treatment in 112 patients with Canadian Cardiovascular Society (CCS) class II angina versus 1346 patients with class III-IV angina using data from the International EECP Patient Registry (IEPR). Treatment with EECP significantly (by at least one CCS class) reduced angina frequency, nitroglycerin use, and improved quality of life in both groups. At 2-year follow-up, 74% of class II and 70% of class III-IV patients remained free of major adverse cardiovascular events (MACE) and continued to demonstrate a durable CCS class improvement over baseline. The robust...Continue Reading

References

Apr 15, 1995·The American Journal of Cardiology·W E LawsonP F Cohn
Jun 14, 2001·Clinical Cardiology·G BarsnessUNKNOWN International EECP Patient Registry Investigators
May 28, 2003·Journal of the American College of Cardiology·Piero O BonettiAmir Lerman
Mar 17, 2004·Coronary Artery Disease·Venkatesan SangareddiS Elangovan
Sep 7, 2004·Clinical Cardiology·William E LawsonUNKNOWN IEPR Investigators
Dec 15, 2004·Circulation·John A SpertusRandall C Thompson

❮ Previous
Next ❯

Citations

Jan 15, 2009·Current Treatment Options in Cardiovascular Medicine·Ozlem Soran
Oct 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·Andrew D MichaelsElizabeth D Kennard
Jul 31, 2012·Current Cardiovascular Risk Reports·Nathan T JenkinsJaume Padilla
Oct 13, 2012·Complementary Therapies in Clinical Practice·Debra L Braverman
Jul 25, 2009·PM & R : the Journal of Injury, Function, and Rehabilitation·Debra L Braverman
Nov 6, 2007·The American Heart Hospital Journal·Gilda EstahbanatyOzlem Soran
Oct 16, 2007·Journal of the American College of Cardiology·Aarush Manchanda, Ozlem Soran
Dec 25, 2012·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Eline WuAnders Broström
Jan 8, 2021·Journal of Clinical Pharmacy and Therapeutics·Jose CaceresDerek Yee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.